<DOC>
	<DOCNO>NCT00000958</DOCNO>
	<brief_summary>To determine safety immunogenicity Env 2-3 combination MTP-PE/MF59 adjuvant adult volunteer HIV infection . By vaccinate HIV infection , perhaps replication ( reproduction ) exist viral strain suppress asymptomatic period early infectious process prolong . One potential way boost HIV antigen-specific CD4 response , may turn increase effectiveness CD8 kill HIV infected cell .</brief_summary>
	<brief_title>A Placebo-Controlled , Phase I , Pilot Clinical Trial Evaluate Safety Immunogenicity ENV 2-3 , Yeast-Derived Recombinant Envelope Protein Human Immunodeficiency Virus-1 , Combination With MTP-PE/MF59 Individuals With HIV Infection ( Placebo Patients Receive MF59 Emulsion Only )</brief_title>
	<detailed_description>By vaccinate HIV infection , perhaps replication ( reproduction ) exist viral strain suppress asymptomatic period early infectious process prolong . One potential way boost HIV antigen-specific CD4 response , may turn increase effectiveness CD8 kill HIV infected cell . Eight patient enter pilot portion study , thirty patient enter Part A fifteen patient enter Part B . In pilot study , patient receive 30 mcg Env 2-3 vaccine plus 0 - 10 mcg MTP-PE/MF59 adjuvant . Patients Part A receive one following : MF59 emulsion ; 100 mcg MTP-PE/MF59 ; 30 mcg Env 2-3 MF59 emulsion ; 30 mcg Env 2-3 vaccine 100 mcg MTP-PE/MF59 . Patients Part B receive either 100 mcg MTP-PE/MF59 30 mcg Env 2-3 vaccine plus 100 mcg MTP-PE/MF59 . Treatment administer day 0 , 28 , 112 , patient follow 10 month . Per amendment , patient may receive two additional dos 30 mcg Env 2-3 placebo MTP-PE/MF59 7 10 month ( Parts A B ) 9 12 month ( Pilot study ) initial inoculation .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<criteria>Inclusion Criteria Patients must : Healthy HIVseropositive adult ( generalize lymphadenopathy , seborrheic dermatitis acceptable ) . Negative HIV plasma culture . Available 6 month followup ( patient Pilot study ) 10 month followup ( patient Parts A B ) . Prior Medication : Required : Part B : Zidovudine ( AZT ) , tolerate dose 500 600 mg/day least 4 month prior entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Evidence psychological disorder past year would impair adherence protocol . Evidence AIDS define opportunistic infection . Prior Medication : Excluded : Any potential immunomodulating agent ( e.g. , isoprinosine , imuthiol , lithium ) within 90 day screen . Immunosuppressive medication past 3 month . Part A : Use zidovudine ( AZT ) 30 day precede 6 month , AZT within last 30 day . Parts A B : Any nonAZT antiretroviral drug . Any investigational agent within past 30 day . Immunoglobulins within past 60 day . Patients may follow prior condition : Evidence psychological disorder past year would impair adherence protocol . History AIDSdefining opportunistic infection . Use illicit drug significant amount alcohol , opinion principal investigator , would interfere compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>